feedback

Course Director

David F. McDermott, MD
David F. McDermott, MD

Beth Israel Deaconess Medical Center
Dana-Farber Harvard Cancer Center Kidney Cancer Program
Harvard Medical School
Boston, Massachusetts

Faculty

Eric Jonasch
Eric Jonasch, MD

VHL Clinical Center
The University of Texas MD Anderson Cancer Center
Houston, Texas

Sumanta Kumar Pal
Sumanta Kumar Pal, MD

City of Hope
Duarte, California

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2017-Jul-13
Expiration Date:2018-Jul-12
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

The treatment armamentarium in advanced renal cell carcinoma (RCC) is expanding rapidly, providing novel targeted, immunotherapeutic, and combination therapy options in the upfront and pretreated disease settings. As newer multitargeted tyrosine kinase inhibitors and immune checkpoint inhibitors are poised to change the landscape in earlier lines of treatment for advanced RCC, clinicians are challenged to adopt a more nuanced and personalized approach to selecting and sequencing different treatment options throughout the advanced disease continuum.

In this activity based on a recent live symposium held at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO 2017), a panel of top experts in kidney cancer combines insights on key clinical concepts and evidence-based practice with personal stories of RCC patients in their care to delineate optimal patient-centric management of advanced RCC.

Upon completion of this activity, participants should be better able to:
  • Evaluate the latest evidence on the benefits and risks of novel approaches, including new targeted agents, immunotherapies, and combination therapies, in advanced renal cell carcinoma (RCC)
  • Counsel advanced RCC patients on effective application of individualized treatment plans that reflect optimal patient-centric selection and sequencing of available options, with considerations of patient- and disease-characteristics and prior treatment history, through multiple lines of therapy
  • Review ongoing clinical trials investigating the latest therapies and/or combination approaches for advanced RCC patients in different disease settings
  • Manage specific disease-related complications or adverse events associated with approved and emerging therapies for advanced RCC

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologic oncologists, and other healthcare professionals involved in the care of patients with RCC.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 13, 2017 - July 12, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

David F. McDermott, MD
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Dana-Farber Harvard Cancer Center Kidney Cancer Program
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

David F. McDermott, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Array BioPharma; Bristol-Myers Squibb; Eisai Inc.; Exelixis, Inc.; Genentech BioOncology; Kidney Cancer Research (NIH); Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.
Grant/Research Support from Kidney Cancer Research (NIH) and Prometheus Laboratories Inc.

David F. McDermott, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various targeted agents and immunotherapies alone or in combinations for renal cell carcinoma.

Faculty

Eric Jonasch, MD
Professor of Medicine
Director, VHL Clinical Center
Department of GU Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Eric Jonasch, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Novartis Pharmaceuticals Corporation.
Grant/Research Support from Exelixis, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.
Advisory Board for Bristol-Myers Squibb; Eisai Inc.; Exelixis, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Eric Jonasch, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various targeted agents and immunotherapies alone or in combinations for renal cell carcinoma.

Sumanta Kumar Pal, MD
Associate Clinical Professor, Genitourinary Malignancies
Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of Hope
Duarte, California

Sumanta Kumar Pal, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Eisai Co., Ltd.; Exelixis, Inc.; Genentech, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Honorarium from Genentech, Inc.

Sumanta Kumar Pal, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: various targeted agents and immunotherapies alone or in combinations for renal cell carcinoma.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported by a medical education grant from Exelixis, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.